Probiotics in atherosclerosis: a pilot study

Probiotics in atherosclerosis: a pilot study - Probiotics in atherosclerosis

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

NL-OMON

Registry ID

NL-OMON30643

Enrollment

Registered

2007-08-08

Start date

2007-10-15

Completion date

Unknown

Last updated

2024-06-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

atherosclerosis

Interventions

The intervention will be administration of probiotics. Imunnological parameters before and after administration will be compared.

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: patients with ANCA associated vasculits increased CD4+/CD28- T-cell counts

Exclusion criteria

Exclusion criteria: No significant immunosupressive therapy

Design outcomes

Primary

Measure	Time frame
- phenotype of the CD4+/CD28- T-cells - measurement of other lymphocyte subsets (NK cells en regulatory T-cells) these cells will be tested on specificity for HSP-60 antigen - quantitive measurement of circulating HSP-60 en HSP-60 antibodies - quantitive measurement of circulating interleuking 10 - selected CD4+/CD28- T-cells stimulation tests with measurement of IL-10 production and intracellular cytokins	—

Measure

Time frame

- phenotype of the CD4+/CD28- T-cells - measurement of other lymphocyte subsets (NK cells en regulatory T-cells) these cells will be tested on specificity for HSP-60 antigen - quantitive measurement of circulating HSP-60 en HSP-60 antibodies - quantitive measurement of circulating interleuking 10 - selected CD4+/CD28- T-cells stimulation tests with measurement of IL-10 production and intracellular cytokins

—

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)